	US 12,419,947 B2
	Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
Ian J. Amanna, Hillsboro, OR (US); and Elizabeth A. Poore, Portland, OR (US)
Assigned to Najit Technologies, Inc., Beaverton, OR (US)
Filed by Najít Technologies, Inc., Beaverton, OR (US)
Filed on Nov. 2, 2023, as Appl. No. 18/500,970.
Application 18/500,970 is a continuation of application No. 16/994,500, filed on Aug. 14, 2020, granted, now 11,844,832.
Application 16/994,500 is a continuation of application No. 16/300,541, granted, now 10,744,198, issued on Aug. 18, 2020, previously published as PCT/US2017/032029, filed on May 10, 2017.
Claims priority of provisional application 62/334,588, filed on May 11, 2016.
Claims priority of provisional application 62/334,406, filed on May 10, 2016.
Claims priority of provisional application 62/334,357, filed on May 10, 2016.
Prior Publication US 2024/0269257 A1, Aug. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 33/40 (2006.01); A61K 39/02 (2006.01); A61K 39/112 (2006.01); A61K 39/145 (2006.01); A61K 39/275 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01); A61P 31/16 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/145 (2013.01) [A61K 33/40 (2013.01); A61K 39/02 (2013.01); A61K 39/0283 (2013.01); A61K 39/105 (2013.01); A61K 39/12 (2013.01); A61K 39/275 (2013.01); A61P 31/14 (2018.01); A61P 31/16 (2018.01); C12N 7/00 (2013.01); A61K 2039/521 (2013.01); A61K 2039/5252 (2013.01); C12N 2760/16131 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16163 (2013.01); C12N 2760/16171 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24163 (2013.01); C12N 2770/24171 (2013.01); C12N 2770/36134 (2013.01); C12N 2770/36163 (2013.01); C12N 2770/36171 (2013.01); Y02A 50/30 (2018.01)]

53 Claims

1. A method for producing an immunogenic vaccine composition comprising an inactivated pathogen, the method comprising:

contacting a pathogen, having an RNA or DNA genome, with a chemical inactivating agent in the presence of one or more inorganic polyatomic oxyanions in an amount and for a time-period sufficient for the chemical inactivating agent to render the pathogen noninfectious while enhancing retention of pathogen immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent without the one or more inorganic polyatomic oxyanions, wherein the inorganic polyatomic oxyanions comprise one or more of:

phosphate (HPO₄²⁻) at a level of at least 50 mM;

sulfate (SO₄²⁻) at a level of at least 25 mM;

trimetaphosphate (P₃O₉³⁻) at a level of at least 0.10 mM; or

triphosphate (P₃O₁₀⁵⁻) at a level of at least 0.05 mM, and wherein the chemical inactivating agent comprises one or more of a chemical oxidizing, alkylating, or crosslinking agent.